BPC-157
Body Protection Compound-157
A synthetic pentadecapeptide derived from a protective protein found in human gastric juice. Extensively studied for tissue repair, gastroprotection, and anti-inflammatory properties across multiple organ systems.
What is it?
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide consisting of 15 amino acids. It is derived from a protein found in human gastric juice, where it is believed to play a role in gastrointestinal mucosal protection and healing. The peptide was first isolated and characterized by researchers studying the cytoprotective properties of gastric secretions.
Since its discovery, BPC-157 has been the subject of extensive preclinical research — with published studies spanning tendon and ligament healing, bone fracture repair, muscle injury recovery, gastrointestinal protection, neuroprotection, and cardiovascular effects. Human exposure is not new: Pliva took the peptide into clinical trials for inflammatory bowel disease in the 2000s under the codes PL-10, PLD-116 and PL 14736, and reported it as safe in that setting. What has never followed is a published, controlled efficacy readout in humans for any of the musculoskeletal uses the compound is now sold for — which is why this entry is graded low evidence rather than moderate.
Mechanism of Action
BPC-157's mechanism of action is not fully elucidated, but preclinical research has identified several pathways through which it appears to exert its effects:
Arrows run from molecule to tissue: each box is what was observed at that level, and where. Every step rests on cell or animal work.
Each step is tagged with where it was shown. A dashed red arrow marks a link the evidence does not establish.
The pathway in words
- BPC-157. A 15-amino-acid partial sequence of a protein first isolated from human gastric juice. Shown in: lab. Source: PubMed 21030672.
- Signalling switched on. More VEGFR2, drawn into the cell, with Akt and eNOS activated in human endothelial cells; FAK and paxillin phosphorylated and more growth hormone receptor in rat tendon fibroblasts. Shown in: cells. Source: PubMed 27847966, 21030672, 25415472.
- Cells behave differently. Endothelial cells form more tube-like structures; tendon fibroblasts survive oxidative stress, spread and migrate faster, and multiply more when growth hormone is added. Shown in: cells. Source: PubMed 27847966, 21030672, 25415472.
- Tissue repair in animals. More vessels in chick embryo membranes, faster return of blood flow to ischaemic rat hind limbs, and faster outgrowth from rat tendon explants. Shown in: animals. Source: PubMed 27847966, 21030672.
- healing never tested in people. In people. The only human report gave it intravenously to two people to check safety. No trial has tested whether it heals anything in humans. Shown in: people. Source: PubMed 40131143.
Angiogenesis / VEGF Pathway
BPC-157 has been shown to promote the formation of new blood vessels by upregulating vascular endothelial growth factor (VEGF) and its receptor VEGFR2. This enhanced blood supply is hypothesized to accelerate tissue repair in tendons, muscles, and the GI tract.
Nitric Oxide (NO) System
Research indicates BPC-157 modulates the nitric oxide system, which plays critical roles in vasodilation, inflammation, and tissue repair. It appears to interact with both NOS (nitric oxide synthase) and the NO-mediated pathway.
Growth Hormone Receptor Expression
A 2018 study demonstrated that BPC-157 enhances growth hormone receptor (GHR) expression in tendon fibroblasts, suggesting a mechanism by which it may accelerate connective tissue repair independent of exogenous GH administration.
Dopaminergic System Modulation
In vitro and in vivo studies have shown BPC-157 interacts with the dopaminergic system, modulating dopamine receptor expression and turnover. This may underlie observed effects on mood, motivation, and neurological recovery in animal models.
FAK-Paxillin Signaling
BPC-157 appears to activate the FAK-paxillin pathway, which is essential for cell migration, adhesion, and tissue organization during wound healing. This mechanism has been observed across multiple tissue types.
Published Research
BPC-157 appears in roughly 200 PubMed-indexed records published between 1991 and 2025, the large majority animal and in vitro work from a small number of groups. Human data is thin and old: a Croatian inflammatory-bowel-disease programme (PL 14736) in the 2000s, and a 2-patient intravenous safety pilot in 2025. Neither speaks to whether it repairs tendon in people. Filter by study type below.
Safety of Intravenous BPC-157 in Humans: A 2-Patient Pilot
Two adults at a private Florida clinic received 10 mg then 20 mg IV infusions; no changes in cardiac, liver, kidney, thyroid or glucose markers and no reported side effects. Both had taken IV BPC-157 before enrolling, there was no control arm, and n=2 supports a safety signal only — not efficacy.
BPC-157 in Orthopaedic Sports Medicine: A Systematic Review
Systematic review of the BPC-157 literature to June 2024 across PubMed, Cochrane and Embase. Finds preclinical support for healing in fracture, tendon, ligament and muscle injury, and notes the compound is used by clinicians and athletes despite lacking FDA approval and being banned in professional sport.
Bile Duct Ligation in Rats: Liver Fibrosis and Portal Hypertension
In rats with ligated bile ducts followed for up to 8 weeks, BPC 157 in drinking water or by injection lessened jaundice, ascites, liver necrosis and fibrosis markers and the rise in liver enzymes, and prevented or quickly reversed portal hypertension. Rat data only, from the Zagreb group that originated the compound.
BPC 157 Against the Standard Angiogenic Growth Factors
A review by the University of Zagreb group behind BPC 157 compares it with EGF, FGF and VEGF across gut, tendon, ligament, muscle and bone healing models and concludes that only BPC 157 was consistently effective in the injury models it reviewed. The models are animal studies, several of them the group's own.
Alkali Burns in Rats: Faster Wound Closure
Topical BPC-157 sped closure of alkali-burn skin wounds in rats, with better granulation tissue, re-epithelialisation and collagen by day 18 and more VEGF in the wound; in human endothelial cells it increased proliferation, migration and tube formation.
BPC-157 Enhances Growth Hormone Receptor Expression in Tendon Fibroblasts
BPC 157 increased growth hormone receptor expression in cultured tendon fibroblasts in a time- and dose-dependent way, proposed as one route by which it may influence tendon healing.
BPC-157 and Blood Vessels
Review of the vascular work on BPC 157 — angiogenic response, NO-system interaction, and vessel recruitment around ischaemic tissue — the basis for the angiogenesis mechanism claimed for this peptide.
Tendon Fibroblasts: Outgrowth, Survival and Migration
In rat Achilles tendon explants and cultured tendon fibroblasts, BPC 157 sped fibroblast outgrowth, improved cell survival under oxidative stress and increased migration in a dose-dependent way without directly increasing proliferation; the authors attribute this to activation of the FAK-paxillin pathway.
Transected Medial Collateral Ligament in Rats
After surgical cutting of the knee's medial collateral ligament, BPC-157 given by injection (10 µg or 10 ng/kg daily), in drinking water or as a cream improved functional, biomechanical and microscopic healing over 90 days.
Transected Sciatic Nerve in Rats
Given shortly after the sciatic nerve was cut (10 µg or 10 ng/kg, by several routes or into a nerve tube), BPC-157 produced faster axonal regeneration, larger motor potentials on EMG and better walking recovery.
Traumatic Brain Injury in Mice and BPC-157
In a falling-weight TBI model in mice, BPC 157 (10 µg or 10 ng/kg i.p.) reduced haemorrhagic lesions and brain oedema and improved the conscious/unconscious/death ratio across a range of impact forces.
BPC-157 as Therapy for Muscle Crush Injury in the Rat
Gastric pentadecapeptide BPC 157 improved healing of crushed gastrocnemius muscle in rats on functional, biomechanical, macroscopic and histological measures.
BPC-157 and Gastric Ulcer Protection in Rats
Intramuscular and intragastric BPC 157 reduced ulcer area and accelerated healing in induced acute and chronic gastric ulcer in rats, with inhibition ratios of 45.7–65.6% at 400–800 ng/kg; the intramuscular route outperformed intragastric.
Transected Achilles Tendon in Rats
Daily injections (10 µg, 10 ng or 10 pg/kg) after the Achilles tendon was cut improved load to failure, stiffness, walking function and collagen formation over 14 days; in culture it counteracted a growth-inhibiting aldehyde in tendon cells.
Segmental Bone Defect in Rabbits
In rabbits with a segmental bone defect, BPC-157 (10 µg or 10 ng/kg, into the defect or into muscle) improved healing on X-ray and histology to a degree comparable with bone marrow or an autologous bone graft; every saline control remained unhealed at 6 weeks.
BPC-157 Interactions with Adrenergic and Dopaminergic Systems
Early pharmacology showing BPC 157 interacts with adrenergic and dopaminergic systems in rodent models — the origin of the claim that it modulates dopamine signalling.
What people say, and what was measured
BPC-157 is the most talked-about peptide on this site and one of the least tested in people. Below are the claims most often made for it, each quoted from where it is said rather than from a seller, set against what has actually been measured.
It heals torn tendons and ligaments, which is why it is called the Wolverine peptide.
Heard in: Forbes Health, The FDA Eased Restrictions On Six Peptides: What Consumers Should Know, which describes the "Wolverine Stack" of TB-500 and BPC-157 (read October 1, 2026). Source
Tendon healing has been shown in rats and in rat tendon cells: BPC-157 made tendon explants grow out faster and raised growth hormone receptor expression in tendon fibroblasts. No controlled trial has tested tendon or ligament healing in people. A 2025 systematic review of 36 studies found one human report, in which 7 of 12 people with chronic knee pain had relief lasting over six months after a single injection, and no clinical safety data at all. PMID: 21030672, 25415472, 40756949
Shown in animals or cells onlyIt is safe, because it is a natural peptide from gastric juice and no side effects are reported.
Heard in: USADA, BPC-157: Experimental Peptide Prohibited, which records that websites advertise it as a research chemical not for human use while also suggesting how someone could use it, and that these are unproven claims (read October 1, 2026). Source
The only published human safety study gave intravenous BPC-157 to two adults at a private clinic and found no change in heart, liver, kidney, thyroid or glucose markers. Two people, no control group. The 2025 systematic review states plainly that animal studies showed no harm but there is no clinical safety data in humans. PMID: 40131143, 40756949
Measured, never givenIt repairs the gut and heals ulcers.
Heard in: HSS Journal, Emerging Use of BPC-157 in Orthopaedic Sports Medicine, which records that BPC-157 is increasingly used by clinicians and athletes despite lacking FDA approval (read October 1, 2026). Source
Protection against gastric ulcers has been shown in rats, where BPC-157 limited damage from several ulcer-causing agents, and in rats with bile duct ligation. The peptide is named for a fragment of a protein in gastric juice, which is where the natural claim comes from. Nothing has been tested in a human gut. PMID: 15052688, 30690000
Shown in animals or cells onlyIt grows new blood vessels, which is how it accelerates recovery from any injury.
Heard in: Grey Peptides listing review, October 1, 2026: listings describe BPC-157 as promoting angiogenesis and systemic healing. Sellers are not named.
Blood-vessel growth is the part of the mechanism with the most laboratory support: BPC-157 activates the VEGFR2 receptor and raises its expression in cells, and the research group behind it has described its effects on blood vessels and on standard angiogenic growth factors. All of this is cells and animals. Nothing links it to faster recovery in a person. PMID: 27847966, 23782145, 29998800
Shown in animals or cells onlyEach claim is quoted from where it is said, never from a seller, and checked as of October 1, 2026 against the studies listed below.
Dosing Data
No BPC-157 regimen has been tested for any condition in people. The one human dose on record is from a 2025 safety pilot: two adults who had used intravenous BPC-157 before received 10 mg, then 20 mg the next day, each infused over an hour, with no side effects reported. The subcutaneous amounts below are community-reported figures from forums and clinic hand-outs; no study has tested them, and the “near the injury” idea is extrapolated from animal work.
Educational information, not medical advice. Each dose above is tagged with its source: an approved label, a published human study, animal data, or amounts reported by users. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose. Full medical disclaimer.
→ Full BPC-157 dosage guide — how it has been dosed in animal studies and in community use, and why no human dose has been established.
→ Blend & Stack Calculator — BPC-157 is also sold in multi-peptide vials; the calculator shows what each draw delivers of every component; our blends and stacks hub sets out what each mix contains and what has been studied.
Side Effects & Contraindications
Reported Side Effects
Based on limited human data and anecdotal reports. Most effects are mild and transient:
Contraindications & Cautions
Limited clinical data means contraindications are not fully established:
Legal Status
BPC-157's legal status varies significantly by country and has been in flux since the FDA's 2023–2025 enforcement actions against compounded peptides.
Frequently Asked Questions
?What is BPC-157 used for?
BPC-157 is primarily studied for tissue repair and healing. Published research has investigated its effects on tendons, ligaments, muscles, the gastrointestinal tract, bone, and neurological tissue. It is not FDA-approved for any therapeutic use in humans.
?Is BPC-157 legal?
Legal status varies by country. In the US, it was placed on the FDA's Category 2 restricted list in 2023 but is expected to be reinstated for compounding under 503A. In many other countries, it is available as a research chemical. See the Legal Status section above for a country-by-country breakdown.
?How do you inject BPC-157?
BPC-157 is most commonly administered via subcutaneous injection, typically near the site of injury for localized effects. It can also be injected intramuscularly. The peptide must first be reconstituted from lyophilized powder using bacteriostatic water. See our Mixing & Administration Guide for step-by-step instructions.
?What are the side effects of BPC-157?
Based on limited human data and anecdotal reports, side effects appear mild and may include nausea, dizziness, injection site redness, and headache. The 2025 pilot study found no serious adverse events at IV doses up to 20mg. However, long-term human safety data is not yet available.
?Can you take BPC-157 orally?
Oral BPC-157 has been studied in animals, mostly for the gut. No published human study measures how much of an oral dose is absorbed, and no US pharmacy currently has a lawful route to compound it, so capsules sold online, including as supplements, sit outside any system that checks their contents. The Defense Department's Operation Supplement Safety states it is not a dietary ingredient.
?How long does BPC-157 take to work?
Anecdotal reports suggest effects may be noticed within a few days to two weeks, depending on the severity of the condition being addressed. Research protocols typically run 4–8 weeks. Individual response varies significantly.
?Does BPC-157 need to be refrigerated?
Yes. Lyophilized (powder) BPC-157 should be stored at -20°C for long-term storage or 2–8°C (refrigerator) for short-term. Once reconstituted, the solution should be refrigerated at 2–8°C and used within 28 days. Avoid repeated freeze-thaw cycles.
?Is BPC-157 a steroid?
No. BPC-157 is a peptide — a short chain of 15 amino acids. It is not a steroid, not a hormone, and does not directly affect testosterone, estrogen, or other steroid hormones. Its mechanism of action involves growth factors, nitric oxide pathways, and cell signaling — entirely different from anabolic steroids.
?Can BPC-157 cause cancer?
This is an area of theoretical concern, not established fact. Because BPC-157 promotes angiogenesis (new blood vessel formation), there is a hypothesis that it could theoretically support tumor growth in individuals with existing cancers. No published study has demonstrated a carcinogenic effect. However, most researchers recommend avoiding BPC-157 in individuals with active malignancies as a precaution.
?What is the difference between BPC-157 and TB-500?
Both are tissue repair peptides, but they work through different mechanisms. BPC-157 primarily promotes angiogenesis, modulates the nitric oxide system, and enhances growth factor receptor expression. TB-500 (Thymosin Beta-4) acts mainly through actin regulation, cell migration, and anti-inflammatory pathways. They are frequently stacked together for synergistic effects.
References
- [review] Sever AZ, et al. "Stable gastric pentadecapeptide BPC 157 in the therapy of the rats with bile duct ligation." Eur J Pharmacol, 2019;847:130-142. PMID: 30690000.
- [review] Chang CH, et al. "The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration." J Appl Physiol, 2011. PMID: 21030672.
- [pubmed] Seiwerth S, et al. "BPC 157 and standard angiogenic growth factors." Life Sci, 2018. PMID: 29998800.
- [pubmed] Lee E, et al. "Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study." Altern Ther Health Med, 2025;31(5):20-24. PMID: 40131143.
- [pubmed] Vasireddi N, et al. "Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review." HSS J, 2025;21(4):485-495. PMID: 40756949.
- [pubmed] Chang CH, et al. "Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts." Molecules, 2014;19(11):19066-77. PMID: 25415472.
- [pubmed] Seiwerth S, et al. "BPC 157 and blood vessels." Curr Pharm Des, 2014;20(7):1121-5. PMID: 23782145.
- [pubmed] Tudor M, et al. "Traumatic brain injury in mice and pentadecapeptide BPC 157 effect." Regul Pept, 2010;160(1-3):26-32. PMID: 19931318.
- [pubmed] Novinscak T, et al. "Gastric pentadecapeptide BPC 157 as an effective therapy for muscle crush injury in the rat." Surg Today, 2008;38(8):716-25. PMID: 18668315.
- [pubmed] Xue XC, et al. "Protective effects of pentadecapeptide BPC 157 on gastric ulcer in rats." World J Gastroenterol, 2004;10(7):1032-6. PMID: 15052688.
- [pubmed] Sikirić P, et al. "Pentadecapeptide BPC 157 interactions with adrenergic and dopaminergic systems in mucosal protection in stress." Dig Dis Sci, 1997;42(3):661-71. PMID: 9073154.
- [pubmed] Hsieh MJ, et al. "Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation." J Mol Med (Berl), 2017;95(3):323-333. PMID: 27847966.
- [pubmed] Huang T, et al. "Body protective compound-157 enhances alkali-burn wound healing in vivo and promotes proliferation, migration, and angiogenesis in vitro." Drug Des Devel Ther, 2015;9:2485-99. PMID: 25995620.
- [pubmed] Cerovecki T, et al. "Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat." J Orthop Res, 2010;28(9):1155-61. PMID: 20225319.
- [pubmed] Gjurasin M, et al. "Peptide therapy with pentadecapeptide BPC 157 in traumatic nerve injury." Regul Pept, 2010;160(1-3):33-41. PMID: 19903499.
- [pubmed] Staresinic M, et al. "Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth." J Orthop Res, 2003;21(6):976-83. PMID: 14554208.
- [pubmed] Sebecić B, et al. "Osteogenic effect of a gastric pentadecapeptide, BPC-157, on the healing of segmental bone defect in rabbits: a comparison with bone marrow and autologous cortical bone implantation." Bone, 1999;24(3):195-202. PMID: 10071911.
Sources & Citations
All research cited on this page links to published studies indexed in PubMed. Molecular data sourced from PubChem (CID 108101). Dosing protocols compiled from published clinical protocols and peer-reviewed research literature. Legal status information current as of April 2026. This page is reviewed and updated monthly.
Medical Disclaimer: This content is for educational and informational purposes only. It is not medical advice, and nothing here is an instruction to obtain or use any compound. Talk to a licensed clinician about your own situation.